Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

PURPOSE: During the alirocumab open-label extension study ODYSSEY OLE (open-label extension; NCT01954394), physicians could adjust alirocumab dosing for enrolled patients, who were diagnosed with heterozygous familial hypercholesterolemia (HeFH) and who had completed previous phase III clinical tria...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Drugs Ther
Main Authors: Langslet, Gisle, Hovingh, G. Kees, Guyton, John R., Baccara-Dinet, Marie T., Letierce, Alexia, Manvelian, Garen, Farnier, Michel
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7334259/
https://ncbi.nlm.nih.gov/pubmed/32363493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-020-06984-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados